- Merck plans to acquire Acceleron Pharma for about $11.5 billion to expand its rare disease drug portfolio.
- Sanofi will acquire New York City-based drugmaker Kadmon for $1.9 billion.
- Pfizer entered into a definitive agreement to buy Canadian cancer drugmaker Trillium Therapeutics for $2.26 billion.
- Bayer has acquired San Diego-based biotech Vividion Therapeutics for $1.5 billion up front, with $500 million in potential success-based milestone payments.
- Sanofi will acquire clinical-stage mRNA therapeutics company Translate Bio for $3.2 billion.
- PerkinElmer is buying antibody and reagents maker BioLegend in a $5.25 billion deal.
